160 related articles for article (PubMed ID: 36878571)
1. New therapies for clear cell ovarian carcinoma.
Stewart J; Cunningham N; Banerjee S
Int J Gynecol Cancer; 2023 Mar; 33(3):385-393. PubMed ID: 36878571
[TBL] [Abstract][Full Text] [Related]
2. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
[TBL] [Abstract][Full Text] [Related]
4. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
5. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
[TBL] [Abstract][Full Text] [Related]
7. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenesis of ovarian clear cell carcinoma.
Gounaris I; Brenton JD
Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
[TBL] [Abstract][Full Text] [Related]
10. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
11. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A; Multinu F; Cosio S; Carinelli S; Ghioni M; Aletti GD
Gynecol Oncol; 2021 Sep; 162(3):741-750. PubMed ID: 34247767
[TBL] [Abstract][Full Text] [Related]
12. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
13. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
Kuroda Y; Chiyoda T; Kawaida M; Nakamura K; Aimono E; Yoshimura T; Takahashi M; Saotome K; Yoshihama T; Iwasa N; Sakai K; Yamagami W; Nishihara H; Aoki D
Gynecol Oncol; 2021 Sep; 162(3):679-685. PubMed ID: 34272091
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
16. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
17. Translational genomics of ovarian clear cell carcinoma.
Khalique S; Lord CJ; Banerjee S; Natrajan R
Semin Cancer Biol; 2020 Apr; 61():121-131. PubMed ID: 31698086
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
20.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
